-
1
-
-
0015305553
-
Combination sequential chemotherapy in advanced reticulum cell sarcoma
-
Levitt M, Marsh JC, DeConti RC, et al. Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer. 1972;29(3):630-636.
-
(1972)
Cancer
, vol.29
, Issue.3
, pp. 630-636
-
-
Levitt, M.1
Marsh, J.C.2
DeConti, R.C.3
-
2
-
-
0016468996
-
Advanced diffuse histiocytic lymphoma, a potentially curable disease
-
DeVita VT Jr, Canellos GP, Chabner B, Schein P, Hubbard SP, Young RC. Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet. 1975;1(7901):248-250.
-
(1975)
Lancet
, vol.1
, Issue.7901
, pp. 248-250
-
-
DeVita Jr., V.T.1
Canellos, G.P.2
Chabner, B.3
Schein, P.4
Hubbard, S.P.5
Young, R.C.6
-
3
-
-
34347378243
-
How I treat patients with diffuse large B-cell lymphoma
-
DOI 10.1182/blood-2007-01-041871
-
Armitage JO. How I treat patients with diffuse large B-cell lymphoma. Blood. 2007;110(1):29-36. (Pubitemid 47026815)
-
(2007)
Blood
, vol.110
, Issue.1
, pp. 29-36
-
-
Armitage, J.O.1
-
4
-
-
0027444652
-
A predictive model for aggressive non-Hodgkin's lymphoma; the International Non-Hodgkin's Lymphoma Prognostic Factors Project
-
[see comments]
-
A predictive model for aggressive non-Hodgkin's lymphoma; the International Non-Hodgkin's Lymphoma Prognostic Factors Project [see comments]. N Engl J Med. 1993;329(14):987-994.
-
(1993)
N Engl J Med
, vol.329
, Issue.14
, pp. 987-994
-
-
-
5
-
-
33847361987
-
The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
-
DOI 10.1182/blood-2006-08-038257
-
Sehn LH, Berry B, Chhanabhai M, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007;109(5):1857-1861. (Pubitemid 46348180)
-
(2007)
Blood
, vol.109
, Issue.5
, pp. 1857-1861
-
-
Sehn, L.H.1
Berry, B.2
Chhanabhai, M.3
Fitzgerald, C.4
Gill, K.5
Hoskins, P.6
Klasa, R.7
Savage, K.J.8
Shenkier, T.9
Sutherland, J.10
Gascoyne, R.D.11
Connors, J.M.12
-
6
-
-
77952477025
-
Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era
-
Ziepert M, Hasenclever D, Kuhnt E, et al. Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(14):2373-2380.
-
(2010)
J Clin Oncol
, vol.28
, Issue.14
, pp. 2373-2380
-
-
Ziepert, M.1
Hasenclever, D.2
Kuhnt, E.3
-
7
-
-
3042813710
-
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: Results of the NHL-B1 trial of the DSHNHL
-
DOI 10.1182/blood-2003-06-2094
-
Pfreundschuh M, Trumper L, Kloess M, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104(3):626-633. (Pubitemid 38970553)
-
(2004)
Blood
, vol.104
, Issue.3
, pp. 626-633
-
-
Pfreundschuh, M.1
Trumper, L.2
Kloess, M.3
Schmits, R.4
Feller, A.C.5
Rudolph, C.6
Reiser, M.7
Hossfeld, D.K.8
Metzner, B.9
Hasenclever, D.10
Schmitz, N.11
Glass, B.12
Rube, C.13
Loeffler, M.14
-
8
-
-
80054750428
-
R-CHOP14 versus R-CHOP21: Results of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma
-
[Abstract #8000]
-
Cunningham D. R-CHOP14 versus R-CHOP21: results of a randomized phase III trial for the treatment of patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma. J Clin Oncol. 2011;29(15S):504s. [Abstract #8000].
-
(2011)
J Clin Oncol
, vol.29
, Issue.15 S
-
-
Cunningham, D.1
-
9
-
-
82755184062
-
R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Results of the second interim analysis of the LNH03-6B GELA Study
-
[Abstract 106]
-
Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): results of the second interim analysis of the LNH03-6B GELA Study. Ann Oncol. 2011;22(suppl 4). [Abstract 106].
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL. 4
-
-
Delarue, R.1
Tilly, H.2
Salles, G.3
-
10
-
-
82255186682
-
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): An open-label randomised phase 3 trial
-
Recher C, Coiffier B, Haioun C, et al. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. The Lancet. 2011;378:1858-1867.
-
(2011)
The Lancet
, vol.378
, pp. 1858-1867
-
-
Recher, C.1
Coiffier, B.2
Haioun, C.3
-
11
-
-
20144369743
-
ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma
-
DOI 10.1056/NEJMoa042040
-
Reyes F, Lepage E, Ganem G, et al. ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. N Engl J Med. 2005;352(12):1197-1205. (Pubitemid 40397261)
-
(2005)
New England Journal of Medicine
, vol.352
, Issue.12
, pp. 1197-1205
-
-
Reyes, F.1
Lepage, E.2
Ganem, G.3
Molina, T.J.4
Brice, P.5
Coiffier, B.6
Morel, P.7
Ferme, C.8
Bosly, A.9
Lederlin, P.10
Laurent, G.11
Tilly, H.12
-
12
-
-
0033985440
-
Testicular lymphoma is associated with a high incidence of extranodal recurrence
-
DOI 10.1002/(SICI)1097-0142(20000101)88:1<154::AID-CNCR21>3.0.CO;2- T
-
Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extranodal recurrence. Cancer. 2000;88(1):154-161. (Pubitemid 30027691)
-
(2000)
Cancer
, vol.88
, Issue.1
, pp. 154-161
-
-
Fonseca, R.1
Habermann, T.M.2
Colgan, J.P.3
O'Neill, B.P.4
White, W.L.5
Witzig, T.E.6
Egan, K.S.7
Martenson, J.A.8
Burgart, L.J.9
Inwards, D.J.10
-
13
-
-
38949211479
-
Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: An International Primary CNS Lymphoma Collaborative Group report
-
DOI 10.1182/blood-2007-07-101402
-
Doolittle ND, Abrey LE, Shenkier TN, et al. Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report. Blood. 2008;111(3):1085-1093. (Pubitemid 351213386)
-
(2008)
Blood
, vol.111
, Issue.3
, pp. 1085-1093
-
-
Doolittle, N.D.1
Abrey, L.E.2
Shenkier, T.N.3
Siegal, T.4
Bromberg, J.E.C.5
Neuwelt, E.A.6
Soussain, C.7
Jahnke, K.8
Johnston, P.9
Illerhaus, G.10
Schiff, D.11
Batchelor, T.12
Montoto, S.13
Kraemer, D.F.14
Zucca, E.15
-
14
-
-
79959954107
-
Diffuse large B-cell lymphoma with involvement of the kidney: Outcome and risk of central nervous system relapse
-
Villa D, Connors JM, Sehn LH, Gascoyne RD, Savage KJ. Diffuse large B-cell lymphoma with involvement of the kidney: outcome and risk of central nervous system relapse. Haematologica. 2011;96(7):1002-1007.
-
(2011)
Haematologica
, vol.96
, Issue.7
, pp. 1002-1007
-
-
Villa, D.1
Connors, J.M.2
Sehn, L.H.3
Gascoyne, R.D.4
Savage, K.J.5
-
15
-
-
0033660953
-
High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma
-
Alvarnas JC, Negrin RS, Horning SJ, et al. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. Biol Blood Marrow Transplant. 2000;6(3A):352-358.
-
(2000)
Biol Blood Marrow Transplant
, vol.6
, Issue.3 A
, pp. 352-358
-
-
Alvarnas, J.C.1
Negrin, R.S.2
Horning, S.J.3
-
16
-
-
85171907933
-
Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell aggressive lymphomas; a potentially curative approach?
-
[Abstract 258]
-
Korfel A, Fischer L, Mohle R, et al. Systemic and intrathecal chemotherapy followed by high-dose chemotherapy with autologous stem cell aggressive lymphomas; a potentially curative approach? Ann Oncol. 2011;22(suppl 4). [Abstract 258].
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL. 4
-
-
Korfel, A.1
Fischer, L.2
Mohle, R.3
-
17
-
-
0033736141
-
Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients
-
Groupe d'Etudes des Lymphomes de l'Adulte
-
Haioun C, Besson C, Lepage E, et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol. 2000;11(6):685-690.
-
(2000)
Ann Oncol
, vol.11
, Issue.6
, pp. 685-690
-
-
Haioun, C.1
Besson, C.2
Lepage, E.3
-
18
-
-
33847617077
-
The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma
-
DOI 10.1093/annonc/mdl434
-
Arkenau HT, Chong G, Cunningham D, et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol. 2007;18(3):541-545. (Pubitemid 46359636)
-
(2007)
Annals of Oncology
, vol.18
, Issue.3
, pp. 541-545
-
-
Arkenau, H.-T.1
Chong, G.2
Cunningham, D.3
Watkins, D.4
Agarwal, R.5
Sirohi, B.6
Trumper, M.7
Norman, A.8
Wotherspoon, A.9
Horwich, A.10
-
19
-
-
33846531961
-
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - A survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL)
-
DOI 10.1093/annonc/mdl327
-
Boehme V, Zeynalova S, Kloess M, et al. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma - a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2007;18(1):149-157. (Pubitemid 46152515)
-
(2007)
Annals of Oncology
, vol.18
, Issue.1
, pp. 149-157
-
-
Boehme, V.1
Zeynalova, S.2
Kloess, M.3
Loeffler, M.4
Kaiser, U.5
Pfreundschuh, M.6
Schmitz, N.7
-
20
-
-
58149354864
-
Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: A 20-year follow-up analysis of SWOG 8516 - The Southwest Oncology Group
-
Bernstein SH, Unger JM, Leblanc M, Friedberg J, Miller TP, Fisher RI. Natural history of CNS relapse in patients with aggressive non-Hodgkin's lymphoma: a 20-year follow-up analysis of SWOG 8516 - the Southwest Oncology Group. J Clin Oncol. 2009;27(1):114-119.
-
(2009)
J Clin Oncol
, vol.27
, Issue.1
, pp. 114-119
-
-
Bernstein, S.H.1
Unger, J.M.2
Leblanc, M.3
Friedberg, J.4
Miller, T.P.5
Fisher, R.I.6
-
21
-
-
77953351708
-
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy
-
Villa D, Connors JM, Shenkier TN, Gascoyne RD, Sehn LH, Savage KJ. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol. 2010;21(5):1046-1052.
-
(2010)
Ann Oncol
, vol.21
, Issue.5
, pp. 1046-1052
-
-
Villa, D.1
Connors, J.M.2
Shenkier, T.N.3
Gascoyne, R.D.4
Sehn, L.H.5
Savage, K.J.6
-
22
-
-
23244455813
-
Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma
-
DOI 10.1016/j.hoc.2005.05.003, PII S0889858805000407, Central Nervous System Lymphomas
-
Bierman P, Giglio P. Diagnosis and treatment of central nervous system involvement in non-Hodgkin's lymphoma. Hematol Oncol Clin North Am. 2005;19(4):597-609. (Pubitemid 41096708)
-
(2005)
Hematology/Oncology Clinics of North America
, vol.19
, Issue.4
, pp. 597-609
-
-
Bierman, P.1
Giglio, P.2
-
23
-
-
0025338486
-
Bone marrow involvement by non-Hodgkin's lymphoma: The clinical significance of morphologic discordance between the lymph node and bone marrow
-
Conlan MG, Bast M, Armitage JO, Weisenburger DD; Nebraska Lymphoma Study Group. Bone marrow involvement by non-Hodgkin's lymphoma: the clinical significance of morphologic discordance between the lymph node and bone marrow. J Clin Oncol. 1990;8(7):1163-1172. (Pubitemid 20195626)
-
(1990)
Journal of Clinical Oncology
, vol.8
, Issue.7
, pp. 1163-1172
-
-
Conlan, M.G.1
Bast, M.2
Armitage, J.O.3
Weisenburger, D.D.4
-
24
-
-
79955015019
-
Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP
-
Sehn LH, Scott DW, Chhanabhai M, et al. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol. 2011;29(11):1452-1457.
-
(2011)
J Clin Oncol
, vol.29
, Issue.11
, pp. 1452-1457
-
-
Sehn, L.H.1
Scott, D.W.2
Chhanabhai, M.3
-
25
-
-
19944428085
-
High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: The role of flow cytometry versus cytology
-
DOI 10.1182/blood-2004-05-1982
-
Hegde U, Filie A, Little RF, et al. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood. 2005;105(2):496-502. (Pubitemid 40070727)
-
(2005)
Blood
, vol.105
, Issue.2
, pp. 496-502
-
-
Hegde, U.1
Filie, A.2
Little, R.F.3
Janik, J.E.4
Grant, N.5
Steinberg, S.M.6
Dunleavy, K.7
Jaffe, E.S.8
Abati, A.9
Stetler-Stevenson, M.10
Wilson, W.H.11
-
26
-
-
63049126670
-
Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: Improved sensitivity of flow cytometry
-
Quijano S, López A, Manuel Sancho J, et al. Identification of leptomeningeal disease in aggressive B-cell non-Hodgkin's lymphoma: improved sensitivity of flow cytometry. J Clin Oncol. 2009;27(9):1462-1469.
-
(2009)
J Clin Oncol
, vol.27
, Issue.9
, pp. 1462-1469
-
-
Quijano, S.1
López, A.2
Manuel Sancho, J.3
-
27
-
-
77957940539
-
Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy
-
Phan J, Mazloom A, Jeffrey Medeiros L, et al. Benefit of consolidative radiation therapy in patients with diffuse large B-cell lymphoma treated with R-CHOP chemotherapy. J Clin Oncol. 2010;28(27):4170-4176.
-
(2010)
J Clin Oncol
, vol.28
, Issue.27
, pp. 4170-4176
-
-
Phan, J.1
Mazloom, A.2
Jeffrey Medeiros, L.3
-
28
-
-
33646004738
-
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: A randomised controlled trial by the Mab-Thera International Trial (MInT) Group
-
Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the Mab-Thera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379-391.
-
(2006)
Lancet Oncol
, vol.7
, Issue.5
, pp. 379-391
-
-
Pfreundschuh, M.1
Trümper, L.2
Osterborg, A.3
-
29
-
-
85171910448
-
6-Year follow-up of the MINT study suggests a role for radiotherapy to bulky disease
-
[Abstract 029]
-
Pfreundschuh M, Kuhnt E, Truemper L, et al. 6-Year follow-up of the MINT study suggests a role for radiotherapy to bulky disease. Ann Oncol. 2011;22(suppl 4). [Abstract 029].
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL. 4
-
-
Pfreundschuh, M.1
Kuhnt, E.2
Truemper, L.3
-
30
-
-
79251540892
-
The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans
-
Dorth JA, Chino JP, Prosnitz LR, et al. The impact of radiation therapy in patients with diffuse large B-cell lymphoma with positive post-chemotherapy FDG-PET or gallium-67 scans. Ann Oncol. 2011;22(2):405-410.
-
(2011)
Ann Oncol
, vol.22
, Issue.2
, pp. 405-410
-
-
Dorth, J.A.1
Chino, J.P.2
Prosnitz, L.R.3
-
31
-
-
57349104217
-
R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: The influence of prior exposure to rituximab on outcome: A GEL/TAMO study
-
Martin A, Conde E, Arnan M, et al. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome: A GEL/TAMO study. Haematologica. 2008;93(12):1829-1836.
-
(2008)
Haematologica
, vol.93
, Issue.12
, pp. 1829-1836
-
-
Martin, A.1
Conde, E.2
Arnan, M.3
-
32
-
-
85171910368
-
Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP and who respond to salvage chemotherapy
-
[Abstract 076]
-
Moore S, Peggs K, Thomson KJ, et al. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP and who respond to salvage chemotherapy. Ann Oncol. 2011;22(suppl 4). [Abstract 076].
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL. 4
-
-
Moore, S.1
Peggs, K.2
Thomson, K.J.3
-
33
-
-
80755143466
-
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: A Bio-CORAL study
-
Thieblemont C, Briere J, Mounier N, et al. The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a Bio-CORAL study. J Clin Oncol. 2011;29(31):4079-4087.
-
(2011)
J Clin Oncol
, vol.29
, Issue.31
, pp. 4079-4087
-
-
Thieblemont, C.1
Briere, J.2
Mounier, N.3
-
34
-
-
80052980811
-
Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP +/- R for eight cycles of CHOP +/- R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgin lymphoma (NHL)
-
Stiff PJ. Randomized phase III U.S./Canadian intergroup trial (SWOG S9704) comparing CHOP +/- R for eight cycles of CHOP +/- R for six cycles followed by autotransplant for patients with high-intermediate (H-Int) or high IPI grade diffuse aggressive non-Hodgin lymphoma (NHL). J Clin Oncol. 2011;29(15S):504s.
-
(2011)
J Clin Oncol
, vol.29
, Issue.15
-
-
Stiff, P.J.1
-
35
-
-
72649090031
-
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: A report from the CIBMTR
-
Lazarus HM, Zhang MJ, Carreras J, et al. A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. Biol Blood Marrow Transplant. 2010;16(1):35-45.
-
(2010)
Biol Blood Marrow Transplant
, vol.16
, Issue.1
, pp. 35-45
-
-
Lazarus, H.M.1
Zhang, M.J.2
Carreras, J.3
-
36
-
-
79954441806
-
Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: An analysis of the European Group for Blood and Marrow Transplantation Registry
-
van Kampen RJ, Canals C, Schouten HC, et al. Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry. J Clin Oncol. 2011;29(10):1342-1348.
-
(2011)
J Clin Oncol
, vol.29
, Issue.10
, pp. 1342-1348
-
-
Van Kampen, R.J.1
Canals, C.2
Schouten, H.C.3
-
37
-
-
72649091641
-
Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: Report of the Société Franòaise de Greffe de Moelle et de thérapie Cellulaire
-
Sirvent A, Dhedin N, Michallet M, et al. Low nonrelapse mortality and prolonged long-term survival after reduced-intensity allogeneic stem cell transplantation for relapsed or refractory diffuse large B cell lymphoma: report of the SociétéFranòaise de Greffe de Moelle et de Thérapie Cellulaire. Biol Blood Marrow Transplant. 2010;16(1):78-85.
-
(2010)
Biol Blood Marrow Transplant
, vol.16
, Issue.1
, pp. 78-85
-
-
Sirvent, A.1
Dhedin, N.2
Michallet, M.3
-
38
-
-
77957066815
-
Surveillance computed tomography scans for patients with lymphoma: Is the risk worth the benefits?
-
Shenoy P, Sinha R, Tumeh JW, Lechowicz MJ, Flowers CR. Surveillance computed tomography scans for patients with lymphoma: is the risk worth the benefits? Clin Lymphoma Myeloma Leuk. 2010;10(4):270-277.
-
(2010)
Clin Lymphoma Myeloma Leuk
, vol.10
, Issue.4
, pp. 270-277
-
-
Shenoy, P.1
Sinha, R.2
Tumeh, J.W.3
Lechowicz, M.J.4
Flowers, C.R.5
-
39
-
-
34547112263
-
67gallium scintigraphy in the evaluation of lymphoma: Relation to histologic subtypes based on the World Health Organization classification
-
DOI 10.1002/cncr.22807
-
Tsukamoto N, Kojima M, Hasegawa M, et al. The usefulness of (18)F-fluorodeoxyglucose positron emission tomography ((18)F-FDG-PET) and a comparison of (18)F-FDG-pet with (67)gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on the World Health Organization classification. Cancer. 2007;110(3):652-659. (Pubitemid 47106156)
-
(2007)
Cancer
, vol.110
, Issue.3
, pp. 652-659
-
-
Tsukamoto, N.1
Kojima, M.2
Hasegawa, M.3
Oriuchi, N.4
Matsushima, T.5
Yokohama, A.6
Saitoh, T.7
Handa, H.8
Endo, K.9
Murakami, H.10
-
40
-
-
36348942458
-
The role of FDG-PET scans in patients with lymphoma
-
DOI 10.1182/blood-2007-06-097238
-
Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507-3516. (Pubitemid 350159614)
-
(2007)
Blood
, vol.110
, Issue.10
, pp. 3507-3516
-
-
Seam, P.1
Juweid, M.E.2
Cheson, B.D.3
-
41
-
-
0036124658
-
Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma
-
DOI 10.1016/S0002-9343(01)01117-2, PII S0002934301011172
-
Wirth A, Seymour JF, Hicks RJ, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma. Am J Med. 2002;112(4):262-268. (Pubitemid 34219438)
-
(2002)
American Journal of Medicine
, vol.112
, Issue.4
, pp. 262-268
-
-
Wirth, A.1
Seymour, J.F.2
Hicks, R.J.3
Ware, R.4
Fisher, R.5
Prince, M.6
MacManus, M.P.7
Ryan, G.8
Januszewicz, H.9
Wolf, M.10
-
42
-
-
53049088385
-
Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma
-
Elstrom RL, Leonard JP, Coleman M, Brown RK. Combined PET and low-dose, noncontrast CT scanning obviates the need for additional diagnostic contrast-enhanced CT scans in patients undergoing staging or restaging for lymphoma. Ann Oncol. 2008;19(10):1770-1773.
-
(2008)
Ann Oncol
, vol.19
, Issue.10
, pp. 1770-1773
-
-
Elstrom, R.L.1
Leonard, J.P.2
Coleman, M.3
Brown, R.K.4
-
43
-
-
34250698039
-
2-[18F]Fluoro-2-Deoxyglucose Positron-Emission Tomography in Staging, Response Evaluation, and Treatment Planning of Lymphomas
-
DOI 10.1016/j.semradonc.2007.02.005, PII S1053429607000161, Lymphoma
-
Specht L. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Semin Radiat Oncol. 2007;17(3):190-197. (Pubitemid 46963030)
-
(2007)
Seminars in Radiation Oncology
, vol.17
, Issue.3
, pp. 190-197
-
-
Specht, L.1
-
44
-
-
0033566341
-
18F- fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging
-
Jerusalem G, Beguin Y, Fassotte MF, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood. 1999;94(2):429-433. (Pubitemid 29323856)
-
(1999)
Blood
, vol.94
, Issue.2
, pp. 429-433
-
-
Jerusalem, G.1
Beguin, Y.2
Fassotte, M.F.3
Najjar, F.4
Paulus, P.5
Rigo, P.6
Fillet, G.7
-
45
-
-
0035863387
-
18F]FDG-PET a valid alternative to conventional diagnostic methods?
-
Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol. 2001;19(2):414-419. (Pubitemid 32112853)
-
(2001)
Journal of Clinical Oncology
, vol.19
, Issue.2
, pp. 414-419
-
-
Spaepen, K.1
Stroobants, S.2
Dupont, P.3
Van Steenweghen, S.4
Thomas, J.5
Vandenberghe, P.6
Vanuytsel, L.7
Bormans, G.8
Balzarini, J.9
De Wolf-Peeters, C.10
Mortelmans, L.11
Verhoef, G.12
-
46
-
-
0033996693
-
18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas
-
Mikhaeel NG, Timothy AR, Hain SF, O'Doherty MJ. 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas. Ann Oncol. 2000;11(suppl 1):147-150.
-
(2000)
Ann Oncol
, vol.11
, Issue.SUPPL. 1
, pp. 147-150
-
-
Mikhaeel, N.G.1
Timothy, A.R.2
Hain, S.F.3
O'Doherty, M.J.4
-
47
-
-
0035676671
-
Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma
-
DOI 10.1046/j.1365-2141.2001.03147.x
-
Naumann R, Vaic A, Beuthien-Baumann B, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol. 2001;115(4):793-800. (Pubitemid 34042895)
-
(2001)
British Journal of Haematology
, vol.115
, Issue.4
, pp. 793-800
-
-
Naumann, R.1
Vaic, A.2
Beuthien-Baumann, B.3
Bredow, J.4
Kropp, J.5
Kittner, T.6
Franke, W.-G.7
Ehninger, G.8
-
48
-
-
61649101731
-
Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: Integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
-
Dupuis J, Itti E, Rahmouni A, et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol. 2009;20(3):503-507.
-
(2009)
Ann Oncol
, vol.20
, Issue.3
, pp. 503-507
-
-
Dupuis, J.1
Itti, E.2
Rahmouni, A.3
-
49
-
-
33947496614
-
Revised response criteria for malignant lymphoma
-
DOI 10.1200/JCO.2006.09.2403
-
Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
-
(2007)
Journal of Clinical Oncology
, vol.25
, Issue.5
, pp. 579-586
-
-
Cheson, B.D.1
Pfistner, B.2
Juweid, M.E.3
Gascoyne, R.D.4
Specht, L.5
Horning, S.J.6
Coiffier, B.7
Fisher, R.I.8
Hagenbeek, A.9
Zucca, E.10
Rosen, S.T.11
Stroobants, S.12
Lister, T.A.13
Hoppe, R.T.14
Dreyling, M.15
Tobinai, K.16
Vose, J.M.17
Connors, J.M.18
Federico, M.19
Diehl, V.20
more..
-
50
-
-
33751576028
-
FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease
-
DOI 10.1002/cncr.22276
-
Kostakoglu L, Goldsmith SJ, Leonard JP, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107(11):2678-2687. (Pubitemid 44845624)
-
(2006)
Cancer
, vol.107
, Issue.11
, pp. 2678-2687
-
-
Kostakoglu, L.1
Goldsmith, S.J.2
Leonard, J.P.3
Christos, P.4
Furman, R.R.5
Atasever, T.6
Chandramouly, A.7
Verma, S.8
Kothari, P.9
Coleman, M.10
-
51
-
-
0036739436
-
Early restaging positron emission tomography with (18)F- fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma
-
Spaepen K, Stroobants S, Dupont P, et al. Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma. Ann Oncol. 2002;13(9):1356-1363.
-
(2002)
Ann Oncol
, vol.13
, Issue.9
, pp. 1356-1363
-
-
Spaepen, K.1
Stroobants, S.2
Dupont, P.3
-
52
-
-
80054098574
-
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
-
Micallef IN, Maurer MJ, Wiseman GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood. 2011;118(15):4053-4061.
-
(2011)
Blood
, vol.118
, Issue.15
, pp. 4053-4061
-
-
Micallef, I.N.1
Maurer, M.J.2
Wiseman, G.A.3
-
53
-
-
77951638691
-
Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma
-
Moskowitz CH, Schöder H, Teruya-Feldstein J, et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-Cell lymphoma. J Clin Oncol. 2010;28(11):1896-1903.
-
(2010)
J Clin Oncol
, vol.28
, Issue.11
, pp. 1896-1903
-
-
Moskowitz, C.H.1
Schöder, H.2
Teruya-Feldstein, J.3
-
54
-
-
69549145060
-
Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone
-
[Abstract 052]
-
Sehn LH, Savage KJ, Hoskins P, et al. Limited-stage DLBCL patients with a negative PET scan following three cycles of R-CHOP have an excellent outcome following abbreviated immuno-chemotherapy alone. Ann Oncol. 2008;19(suppl 4). [Abstract 052].
-
(2008)
Ann Oncol
, vol.19
, Issue.SUPPL. 4
-
-
Sehn, L.H.1
Savage, K.J.2
Hoskins, P.3
-
55
-
-
80051600214
-
Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy
-
Corazzelli G, Frigeri F, Arcamone M, et al. Biweekly rituximab, cyclophosphamide, vincristine, non-pegylated liposome-encapsulated doxorubicin and prednisone (R-COMP-14) in elderly patients with poor-risk diffuse large B-cell lymphoma and moderate to high 'life threat' impact cardiopathy. Br J Haematol. 2011;154(5):579-589.
-
(2011)
Br J Haematol
, vol.154
, Issue.5
, pp. 579-589
-
-
Corazzelli, G.1
Frigeri, F.2
Arcamone, M.3
-
56
-
-
79955485192
-
Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas
-
Weidmann E, Neumann A, Fauth F, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol. 2011;22(8):1839-1844.
-
(2011)
Ann Oncol
, vol.22
, Issue.8
, pp. 1839-1844
-
-
Weidmann, E.1
Neumann, A.2
Fauth, F.3
-
57
-
-
79955812219
-
R-CHOP with etoposide substituted for doxorubicin (R-CEOP): Excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines
-
Moccia AA, Schaff K, Hoskins P, et al. R-CHOP with etoposide substituted for doxorubicin (R-CEOP): excellent outcome in diffuse large B cell lymphoma for patients with a contraindication to anthracyclines. Blood. 2009;114(22):170.
-
(2009)
Blood
, vol.114
, Issue.22
, pp. 170
-
-
Moccia, A.A.1
Schaff, K.2
Hoskins, P.3
-
59
-
-
53249123632
-
Plasmablastic lymphoma
-
Swerdlow SH, Campo E, Harris NL, et al, eds. 4th ed. Lyon, France: IARC Press
-
Stein H, Harris NL, Campo E. Plasmablastic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:256-257.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 256-257
-
-
Stein, H.1
Harris, N.L.2
Campo, E.3
-
61
-
-
66349087065
-
Lymphomatoid granulomatosis
-
Swerdlow SH, Campo E, Harris NL, et al, eds. 4th ed. Lyon, France: IARC Press
-
Pittaluga S, Wilson WH, Jaffe ES. Lymphomatoid granulomatosis. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:247-249.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 247-249
-
-
Pittaluga, S.1
Wilson, W.H.2
Jaffe, E.S.3
-
62
-
-
0029905515
-
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha2b
-
Wilson WH, Kingma DW, Raffeld M, Wittes RE, Jaffe ES. Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. Blood. 1996;87(11):4531-4537. (Pubitemid 26162358)
-
(1996)
Blood
, vol.87
, Issue.11
, pp. 4531-4537
-
-
Wilson, W.H.1
Kingma, D.W.2
Raffeld, M.3
Wittes, R.E.4
Jaffe, E.S.5
-
63
-
-
79960685420
-
How I treat primary CNS lymphoma
-
Ferreri AJ. How I treat primary CNS lymphoma. Blood. 2011;118(3):510-522.
-
(2011)
Blood
, vol.118
, Issue.3
, pp. 510-522
-
-
Ferreri, A.J.1
-
64
-
-
79953304056
-
Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy
-
Khimani NB, Ng AK, Chen YH, Catalano P, Silver B, Mauch PM. Salvage radiotherapy in patients with recurrent or refractory primary or secondary central nervous system lymphoma after methotrexate-based chemotherapy. Ann Oncol. 2011;22(4):979-984.
-
(2011)
Ann Oncol
, vol.22
, Issue.4
, pp. 979-984
-
-
Khimani, N.B.1
Ng, A.K.2
Chen, Y.H.3
Catalano, P.4
Silver, B.5
Mauch, P.M.6
-
65
-
-
79960239204
-
First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: Final results of an international phase II trial
-
Vitolo U, Chiappella A, Ferreri AJ, et al. First-line treatment for primary testicular diffuse large B-cell lymphoma with rituximab-CHOP, CNS prophylaxis, and contralateral testis irradiation: final results of an international phase II trial. J Clin Oncol. 2011;29(20):2766-2772.
-
(2011)
J Clin Oncol
, vol.29
, Issue.20
, pp. 2766-2772
-
-
Vitolo, U.1
Chiappella, A.2
Ferreri, A.J.3
-
66
-
-
18744370725
-
Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group
-
Zucca E, Conconi A, Mughal TI, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol. 2003;21(1):20-27.
-
(2003)
J Clin Oncol
, vol.21
, Issue.1
, pp. 20-27
-
-
Zucca, E.1
Conconi, A.2
Mughal, T.I.3
-
67
-
-
0029060546
-
Testicular lymphoma: Late relapses and poor outcome despite doxorubicin-based therapy
-
Touroutoglou N, Dimopoulos MA, Younes A, et al. Testicular lymphoma: late relapses and poor outcome despite doxorubicin-based therapy. J Clin Oncol. 1995;13(6):1361-1367.
-
(1995)
J Clin Oncol
, vol.13
, Issue.6
, pp. 1361-1367
-
-
Touroutoglou, N.1
Dimopoulos, M.A.2
Younes, A.3
-
68
-
-
84856646816
-
Primary cutaneous DLBCL, leg type
-
Swerdlow SH, Campo E, Harris NL, et al, eds. 4th ed. Lyon, France: IARC Press
-
Meijer CJLM, Vergier B, Duncan LM, Willemze R. Primary cutaneous DLBCL, leg type. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:242.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 242
-
-
Meijer, C.J.L.M.1
Vergier, B.2
Duncan, L.M.3
Willemze, R.4
-
69
-
-
67649451073
-
Primary cutaneous follicle centre lymphoma
-
Swerdlow SH, Campo E, Harris NL, et al, eds. 4th ed. Lyon, France: IARC Press
-
Willemze R, Swerdlow SH, Harris NL, Vergier B. Primary cutaneous follicle centre lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:227-228.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 227-228
-
-
Willemze, R.1
Swerdlow, S.H.2
Harris, N.L.3
Vergier, B.4
-
70
-
-
67749137630
-
Intravascular large B-cell lymphoma
-
Swerdlow SH, Campo E, Harris NL, et al, eds. 4th ed. Lyon, France: IARC Press
-
Nakamura S, Ponzoni M, Campo E. Intravascular large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:252-253.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 252-253
-
-
Nakamura, S.1
Ponzoni, M.2
Campo, E.3
-
71
-
-
52649165593
-
The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma
-
Ferreri AJ, Dognini GP, Bairey O, et al. The addition of rituximab to anthracycline-based chemotherapy significantly improves outcome in 'Western' patients with intravascular large B-cell lymphoma. Br J Haematol. 2008;143(2):253-257.
-
(2008)
Br J Haematol
, vol.143
, Issue.2
, pp. 253-257
-
-
Ferreri, A.J.1
Dognini, G.P.2
Bairey, O.3
-
72
-
-
69149087791
-
Presentation and management of intravascular large B-cell lymphoma
-
Shimada K, Kinoshita T, Naoe T, Nakamura S. Presentation and management of intravascular large B-cell lymphoma. Lancet Oncol. 2009;10(9):895-902.
-
(2009)
Lancet Oncol
, vol.10
, Issue.9
, pp. 895-902
-
-
Shimada, K.1
Kinoshita, T.2
Naoe, T.3
Nakamura, S.4
-
73
-
-
85171929485
-
Prognostic significance of circulating lymphoma cells in newly diagnosed diffuse large B-cell lymphoma (DLBCL)
-
[Abstract 2947]
-
Muringampurath-John D, Flowers CR, Jabbar AA, et al. Prognostic significance of circulating lymphoma cells in newly diagnosed diffuse large B-cell lymphoma (DLBCL). Blood. 2009;114(22):1151. [Abstract 2947].
-
(2009)
Blood
, vol.114
, Issue.22
, pp. 1151
-
-
Muringampurath-John, D.1
Flowers, C.R.2
Jabbar, A.A.3
-
74
-
-
70349691319
-
B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma
-
Swerdlow SH, Campo E, Harris NL, et al, eds. 4th ed. Lyon, France: IARC Press
-
Jaffe ES, Stein H, Swerdlow SH, Campo E, Pileri SA, Harris NL. B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:267-268.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 267-268
-
-
Jaffe, E.S.1
Stein, H.2
Swerdlow, S.H.3
Campo, E.4
Pileri, S.A.5
Harris, N.L.6
-
75
-
-
80054045437
-
BCL2 and MYC dual-hit lymphoma/leukemia
-
Tomita N. BCL2 and MYC dual-hit lymphoma/leukemia. J Clin Exp Hematop. 2011;51(1):7-12.
-
(2011)
J Clin Exp Hematop
, vol.51
, Issue.1
, pp. 7-12
-
-
Tomita, N.1
-
76
-
-
79952154009
-
Double-hit B-cell lymphomas
-
Aukema SM, Siebert R, Schuuring E, et al. Double-hit B-cell lymphomas. Blood. 2011;117(8):2319-2331.
-
(2011)
Blood
, vol.117
, Issue.8
, pp. 2319-2331
-
-
Aukema, S.M.1
Siebert, R.2
Schuuring, E.3
-
77
-
-
77954752069
-
Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab
-
Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28(20):3360-3365.
-
(2010)
J Clin Oncol
, vol.28
, Issue.20
, pp. 3360-3365
-
-
Barrans, S.1
Crouch, S.2
Smith, A.3
-
78
-
-
70449589073
-
MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy
-
Savage KJ, Johnson NA, Ben-Neriah S, et al. MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy. Blood. 2009;114(17):3533-3537.
-
(2009)
Blood
, vol.114
, Issue.17
, pp. 3533-3537
-
-
Savage, K.J.1
Johnson, N.A.2
Ben-Neriah, S.3
-
79
-
-
79955868541
-
The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective
-
Salaverria I, Siebert R. The gray zone between Burkitt's lymphoma and diffuse large B-cell lymphoma from a genetics perspective. J Clin Oncol. 2011;29(14):1835-1843.
-
(2011)
J Clin Oncol
, vol.29
, Issue.14
, pp. 1835-1843
-
-
Salaverria, I.1
Siebert, R.2
-
80
-
-
78751580704
-
Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL
-
Maruyama D, Watanabe T, Maeshima AM, et al. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL. Int J Hematol. 2010;92(5):732-743.
-
(2010)
Int J Hematol
, vol.92
, Issue.5
, pp. 732-743
-
-
Maruyama, D.1
Watanabe, T.2
Maeshima, A.M.3
-
81
-
-
84855281681
-
MYC + aggressive-B-cell lymphomas: Novel therapy of untreated Burkitt lymhoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R
-
[Abstract 071]
-
Dunleavy K, Pittaluga S, Wayne AS, et al. MYC + aggressive-B-cell lymphomas: novel therapy of untreated Burkitt lymhoma (BL) and MYC + diffuse large B-cell lymphoma (DLBCL) with DA-EPOCH-R. Ann Oncol. 2011;22(suppl 4). [Abstract 071].
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL. 4
-
-
Dunleavy, K.1
Pittaluga, S.2
Wayne, A.S.3
-
82
-
-
79953879650
-
Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma
-
Eberle FC, Rodriguez-Canales J, Wei L, et al. Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Haematologica. 2011;96(4):558-566.
-
(2011)
Haematologica
, vol.96
, Issue.4
, pp. 558-566
-
-
Eberle, F.C.1
Rodriguez-Canales, J.2
Wei, L.3
-
83
-
-
84856646807
-
Untreated primary mediastinal B-cell (PMBL) and mediastinal Grey Zone (MGZL) lymphomas: Comparison of biological features and clinical outcome following DA-EPOCH-R without radiation
-
[Abstract 150]
-
Dunleavy K, Pittaluga S, Shovlin M, G et al. Untreated primary mediastinal B-cell (PMBL) and mediastinal Grey Zone (MGZL) lymphomas: comparison of biological features and clinical outcome following DA-EPOCH-R without radiation. Ann Oncol. 2011;22(suppl 4). [Abstract 150].
-
(2011)
Ann Oncol
, vol.22
, Issue.SUPPL. 4
-
-
Dunleavy, K.1
Pittaluga, S.2
Shovlin, M.G.3
-
84
-
-
79952459294
-
Two cases of mediastinal gray zone lymphoma
-
Minami J, Dobashi N, Asai O, et al. Two cases of mediastinal gray zone lymphoma. J Clin Exp Hematop. 2010;50(2):143-149.
-
(2010)
J Clin Exp Hematop
, vol.50
, Issue.2
, pp. 143-149
-
-
Minami, J.1
Dobashi, N.2
Asai, O.3
-
85
-
-
0034598746
-
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
-
DOI 10.1038/35000501
-
Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403(6769):503-511. (Pubitemid 30082188)
-
(2000)
Nature
, vol.403
, Issue.6769
, pp. 503-511
-
-
Alizadeh, A.A.1
Elsen, M.B.2
Davis, R.E.3
Ma, C..L.4
Lossos, I.S.5
Rosenwald, A.6
Boldrick, J.C.7
Sabet, H.8
Tran, T.9
Yu, X.10
Powell, J.I.11
Yang, L.12
Maru, G.E.13
Moore, T.14
Hudson Jr., J.15
Lu, L.16
Lewis, D.B.17
Tibshirani, R.18
Sherlock, G.19
Chan, W.C.20
Greiner, T.C.21
Weisenburger, D.D.22
Armitage, J.O.23
Warnke, R.24
Levy, R.25
Wilson, W.26
Grever, M.R.27
Byrd, J.C.28
Botstein, D.29
Brown, P.O.30
Staudt, L.M.31
more..
-
86
-
-
0037142053
-
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
-
Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(25):1937-1947.
-
(2002)
N Engl J Med
, vol.346
, Issue.25
, pp. 1937-1947
-
-
Rosenwald, A.1
Wright, G.2
Chan, W.C.3
-
87
-
-
67650398258
-
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
-
Dunleavy K, Pittaluga S, Czuczman MS, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113(24):6069-6076.
-
(2009)
Blood
, vol.113
, Issue.24
, pp. 6069-6076
-
-
Dunleavy, K.1
Pittaluga, S.2
Czuczman, M.S.3
-
88
-
-
79952154013
-
Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
-
Ruan J, Martin P, Furman RR, et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol. 2010;29(6):690-697.
-
(2010)
J Clin Oncol
, vol.29
, Issue.6
, pp. 690-697
-
-
Ruan, J.1
Martin, P.2
Furman, R.R.3
-
89
-
-
70249128366
-
Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: A rare clinicopathologic entity with poor prognosis
-
Laurent C, Do C, Gascoyne RD, et al. Anaplastic lymphoma kinase-positive diffuse large B-cell lymphoma: a rare clinicopathologic entity with poor prognosis. J Clin Oncol. 2009;27(25):4211-4216.
-
(2009)
J Clin Oncol
, vol.27
, Issue.25
, pp. 4211-4216
-
-
Laurent, C.1
Do, C.2
Gascoyne, R.D.3
-
90
-
-
67650235829
-
ALK-positive large B-cell lymphoma
-
Swerdlow SH, Campo E, Harris NL, et al, eds. 4th ed. Lyon, France: IARC Press
-
Delsol G, Campo E, Gascoyne RD. ALK-positive large B-cell lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:254-255.
-
(2008)
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
, pp. 254-255
-
-
Delsol, G.1
Campo, E.2
Gascoyne, R.D.3
-
91
-
-
78049425319
-
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
-
Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363(18):1693-1703.
-
(2010)
N Engl J Med
, vol.363
, Issue.18
, pp. 1693-1703
-
-
Kwak, E.L.1
Bang, Y.J.2
Camidge, D.R.3
-
92
-
-
80053190602
-
Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)
-
[abstract 8032]
-
Pro B. Durable remissions with brentuximab vedotin (SGN-35): updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL) [abstract 8032]. J Clin Oncol. 2011;29(15S):512s.
-
(2011)
J Clin Oncol
, vol.29
, Issue.15 S
-
-
Pro, B.1
|